[go: up one dir, main page]

AR023130A1 - Composiciones para promover el crecimiento - Google Patents

Composiciones para promover el crecimiento

Info

Publication number
AR023130A1
AR023130A1 ARP000101281A ARP000101281A AR023130A1 AR 023130 A1 AR023130 A1 AR 023130A1 AR P000101281 A ARP000101281 A AR P000101281A AR P000101281 A ARP000101281 A AR P000101281A AR 023130 A1 AR023130 A1 AR 023130A1
Authority
AR
Argentina
Prior art keywords
compositions
promote growth
inhibitors
growth
promote
Prior art date
Application number
ARP000101281A
Other languages
English (en)
Original Assignee
Ferrini Cristina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrini Cristina filed Critical Ferrini Cristina
Publication of AR023130A1 publication Critical patent/AR023130A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Inhibidores de dipeptidil peptidasa IV y composiciones farmacéuticas que comprenden estos inhibidores son utiles en el tratamiento de corta estatura debidoa la deficiencia de la Hormona de Crecimiento y para promover el crecimiento de tejido GH-depen diente o recrecimiento.
ARP000101281A 1999-03-23 2000-03-22 Composiciones para promover el crecimiento AR023130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9906715.9A GB9906715D0 (en) 1999-03-23 1999-03-23 Compositions for promoting growth

Publications (1)

Publication Number Publication Date
AR023130A1 true AR023130A1 (es) 2002-09-04

Family

ID=10850230

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101281A AR023130A1 (es) 1999-03-23 2000-03-22 Composiciones para promover el crecimiento

Country Status (26)

Country Link
US (1) US6521644B1 (es)
EP (1) EP1171121B1 (es)
JP (1) JP2002539244A (es)
KR (1) KR100704348B1 (es)
CN (1) CN1359293A (es)
AR (1) AR023130A1 (es)
AT (1) ATE297728T1 (es)
AU (1) AU772421B2 (es)
CA (1) CA2366926A1 (es)
CZ (1) CZ20013411A3 (es)
DE (1) DE60020825T2 (es)
GB (1) GB9906715D0 (es)
HK (1) HK1048589A1 (es)
HU (1) HUP0200391A3 (es)
IL (2) IL145568A0 (es)
MX (1) MXPA01009610A (es)
MY (1) MY124214A (es)
NO (1) NO20014608L (es)
NZ (1) NZ514450A (es)
PL (1) PL195529B1 (es)
RU (1) RU2242228C2 (es)
TR (1) TR200102648T2 (es)
TW (1) TWI239246B (es)
UA (1) UA73115C2 (es)
WO (1) WO2000056297A2 (es)
ZA (1) ZA200108082B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2002316437A1 (en) * 2001-06-27 2003-03-03 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7309714B2 (en) * 2002-12-04 2007-12-18 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) * 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AP2007004234A0 (en) * 2005-04-22 2007-12-31 Alantos Pharm Holding Dipeptidyl peptidase-IV inhibitors
GEP20135838B (en) * 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
PE20070622A1 (es) * 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
EP1931350B2 (en) * 2005-09-14 2021-08-04 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US8455533B2 (en) 2009-09-02 2013-06-04 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063360T3 (es) * 1989-06-16 1995-01-01 Upjohn Co Analogos potentes de grf, estabilizados.
CA2080474A1 (en) 1990-04-14 1991-10-15 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
HUT63857A (en) * 1990-11-14 1993-10-28 Upjohn Co Process for producing grf-analogs
RU2114119C1 (ru) * 1990-12-13 1998-06-27 Дзе Апджон Компани Слитой белок и способ выделения слитого белка
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
DE69233671T2 (de) * 1991-10-22 2007-10-18 New England Medical Center Hospitals, Inc., Boston Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
JPH09295946A (ja) * 1995-05-16 1997-11-18 Mitsui Pharmaceut Inc 医薬組成物
JPH09308259A (ja) * 1996-05-17 1997-11-28 Toshiba Lighting & Technol Corp 電源装置、放電ランプ点灯装置及び照明装置
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function

Also Published As

Publication number Publication date
US6521644B1 (en) 2003-02-18
MXPA01009610A (es) 2002-07-02
NZ514450A (en) 2002-11-26
TR200102648T2 (tr) 2001-12-21
PL350796A1 (en) 2003-02-10
KR20010108389A (ko) 2001-12-07
IL145568A0 (en) 2002-06-30
TWI239246B (en) 2005-09-11
KR100704348B1 (ko) 2007-04-05
ATE297728T1 (de) 2005-07-15
HUP0200391A2 (en) 2002-06-29
WO2000056297A2 (en) 2000-09-28
MY124214A (en) 2006-06-30
NO20014608L (no) 2001-10-31
ZA200108082B (en) 2002-12-24
UA73115C2 (en) 2005-06-15
EP1171121A2 (en) 2002-01-16
HK1048589A1 (zh) 2003-04-11
JP2002539244A (ja) 2002-11-19
AU3318600A (en) 2000-10-09
DE60020825T2 (de) 2006-05-04
AU772421B2 (en) 2004-04-29
GB9906715D0 (en) 1999-05-19
IL145568A (en) 2007-09-20
HUP0200391A3 (en) 2002-11-28
EP1171121B1 (en) 2005-06-15
RU2242228C2 (ru) 2004-12-20
CZ20013411A3 (cs) 2002-04-17
DE60020825D1 (de) 2005-07-21
PL195529B1 (pl) 2007-09-28
WO2000056297A3 (en) 2001-01-25
NO20014608D0 (no) 2001-09-21
CN1359293A (zh) 2002-07-17
CA2366926A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
AR023130A1 (es) Composiciones para promover el crecimiento
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ES2152256T3 (es) Metodo para prevenir el calculo dental en animales domesticos.
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE212841T1 (de) Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
TR200200278T2 (tr) Kalsilitik bileşimler
BR0111785A (pt) Composições e métodos para tratamento de candidìase
UY26498A1 (es) Pirroles sustituidos
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung

Legal Events

Date Code Title Description
FB Suspension of granting procedure